Showing 1901-1910 of 3223 results for "".
- Edward J. Holland, MD, to Join Alcon as Member of the Research and Development Teamhttps://modernod.com/news/edward-j-holland-md-to-join-alcon-as-member-of-the-research-and-development-team/2481000/Alcon announced that Edward J. Holland, MD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Holland is a thought leader in ophthalmology, specializing in the field of cornea and the ocular surface. He will serve as an enterprise Senior Scientifi
- New App Allows Surgeons to Search for FDA Approved IOLshttps://modernod.com/news/new-app-allows-surgeons-to-search-for-fda-approved-iols/2480969/Matt Hirabayashi, MD, of eyeflymd.com, and Gurpal Virdi, MD, of Eyelabs.ai, have developed an app called “eyeSpace,” which is designed to allow surgeons and trainees to
- Bausch + Lomb Announces Efficiency-Enhancing Upgrades for Stellaris Elite Vision Enhancement Systemhttps://modernod.com/news/bausch-lomb-announces-efficiency-enhancing-upgrades-for-stellaris-elite-vision-enhancement-system/2480960/Bausch + Lomb announced the first in a series of upgrades for the Stellaris Elite vision enhancement system designed to enhance efficiency. The upgrades include an increase to the maximum vacuum setting from 600 to 660 mmHg and an enhancement to the removable valve caps in the troc
- Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trialhttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoints-in-dry-eye-disease-chamber-crossover-clinical-trial/2480957/Aldeyra Therapeutics announced the achievement of the primary endpoints in a sequence-randomized, double-masked, vehicle-controlled crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was st
- SAV-IOL Continues Progress on Electronic IOL Projecthttps://modernod.com/news/sav-iol-continues-progress-on-electronic-iol-project/2480946/SAV-IOL (Swiss Advanced Vision) provided an update on its progress toward making the first active, electronic IOL through their R-TASC Project. SAV-IOL first launched the R-TASC Project idea in 2018. "Current IOLs on the market suffer
- Graybug Announces Review of Strategic Alternativeshttps://modernod.com/news/graybug-announces-review-of-strategic-alternatives/2480935/Graybug Vision announced that its Board of Directors will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. As part of this process, the company will explore the potential for an acquisition, company sale, merger, divesti
- Ace Vision Group Appoints Elizabeth Yeu, MD, as Chief Strategic Advisorhttps://modernod.com/news/ace-vision-group-appoints-elizabeth-yeu-md-as-chief-strategic-advisor/2480922/Ace Vision Group announced that Elizabeth Yeu, MD, partner at Virginia Eye Consultants, has been appointed to the role of chief strategic advisor. In her new position, Dr. Yeu will manage AVG's clinical advancement strategy. As a surgeon, researcher, and educator, Dr.
- Lensar Receives FDA Clearance of the ALLY Adaptive Cataract Treatment Systemhttps://modernod.com/news/lensar-receives-fda-clearance-of-the-ally-adaptive-cataract-treatment-system/2480910/Lensar announced FDA 510(k) clearance for its ALLY Adaptive Cataract Treatment System. ALLY is the first FDA-cleared platform to enable cataract surgeons to complete the femtosecond-laser-assisted cataract surgery (FLACS) procedure in a single, sterile environment. "The (
- Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-tranquility2-trial-in-dry-eye-disease/2480902/Aldeyra Therapeutics announced the achievement of the primary endpoint in the phase 3 TRANQUILITY-2 clinical trial (TRANQUILITY-2) of reproxalap, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was statistically superior to vehicle for each of the two presp
- Phase 3 Clinical Study IND Accepted in China for Alimera’s Fluocinolone Acetonide Intravitreal Implanthttps://modernod.com/news/phase-3-clinical-study-ind-accepted-in-china-for-alimeras-fluocinolone-acetonide-intravitreal-implant/2480901/Alimera Sciences announced that its partner, Ocumension Therapeutics, received approval from the National Medical Products Administration for its IND application to begin the phase 3 clinical study for fluocinolone acetonide intravitreal implant in support of a filing for marketing approval